Revolution Medicines Form 4: 10b5-1 sales and option exercises

Rhea-AI Filing Summary

Revolution Medicines (RVMD) insider activity: On October 16–17, 2025, President & CEO and director Mark A. Goldsmith exercised 20,000 stock options at $1.12 and sold 20,000 common shares pursuant to a Rule 10b5-1(c) trading plan adopted on December 19, 2024. Sales were 10,000 shares at a weighted average $50.4701 on Oct 16 and 10,000 shares at $55 on Oct 17.

Following these transactions, he directly beneficially owns 452,309 shares, which includes 193,475 restricted stock units. He also reports indirect holdings of 20,424, 20,424, and 465,604 shares held in family trusts. After the option exercises, 26,479 stock options remain beneficially owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2025		M(1)		10,000	A	$1.12	462,309(2)	D
Common Stock	10/16/2025		S(1)		10,000	D	$50.4701(3)	452,309(2)	D
Common Stock	10/17/2025		M(1)		10,000	A	$1.12	462,309(2)	D
Common Stock	10/17/2025		S(1)		10,000	D	$55	452,309(2)	D
Common Stock								20,424	I	Trust(4)
Common Stock								20,424	I	Trust(5)
Common Stock								465,604	I	Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	10/16/2025		M(1)			10,000	03/29/2022	04/19/2028	Common Stock	10,000	$0	36,479	D
Stock Option (Right to Buy)	$1.12	10/17/2025		M(1)			10,000	03/29/2022	04/19/2028	Common Stock	10,000	$0	26,479	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

2. Includes 193,475 restricted stock units.

3. This transaction was executed in multiple trades at prices ranging from $50.00 to $50.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Held by Jonathan Goldsmith Revocable Trust.

5. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

6. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RVMD's CEO report on Form 4?

Mark A. Goldsmith exercised 20,000 options at $1.12 and sold 20,000 shares on Oct 16–17, 2025 under a Rule 10b5-1(c) plan.

At what prices were RVMD shares sold?

He sold 10,000 shares at a weighted average $50.4701 on Oct 16 and 10,000 shares at $55 on Oct 17.

How many RVMD shares does the CEO own after these trades?

Direct beneficial ownership is 452,309 shares, including 193,475 RSUs.

What indirect RVMD holdings were reported?

Indirect holdings are 20,424, 20,424, and 465,604 shares held in specified trusts.

How many options remain after the exercises?

He reports 26,479 stock options beneficially owned after the transactions.

Was the trading under a 10b5-1 plan?

Yes. Transactions were made under a 10b5-1 plan adopted on December 19, 2024.